DeepMed Research

JAZZ PHARMACEUTICALS FRANCE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2003-01-01

Employees: -

Market Cap: -

Website: https://www.jazzpharma.com/careers/open-positions/

Clinical Trials

Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting

Active, not recruiting

Conditions: Seizures

Interventions: Drug: Epidiolex

First Posted Date: 2023-03-16

Last Posted Date: 2025-04-13

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 158

Registration Number: NCT05772429

Locations: 🇫🇷
APHP Pitié Salpetriere- service adulte, Paris, France
🇫🇷
APHP Robert Debré - service enfant, Paris, France
🇫🇷
APHP Necker - service enfant, Paris, France

and more 26 locations

A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder

Phase 2

Withdrawn

Conditions: Irritability Associated With Autism Spectrum Disorder
Autism Spectrum Disorder
ASD

Interventions: Drug: JZP541
Other: Placebo

First Posted Date: 2023-02-17

Last Posted Date: 2024-11-08

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT05733390

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Phase 1

Recruiting

Conditions: Ewing Sarcoma
Relapsed Ewing Sarcoma
Refractory Ewing Sarcoma

Interventions: Drug: Lurbinectedin

First Posted Date: 2023-02-17

Last Posted Date: 2025-01-23

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05734066

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Stanford Children's Health, Palo Alto, California, United States
🇺🇸
Childrens National Hospital Michigan, Washington, District of Columbia, United States

and more 12 locations

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: JZP441

First Posted Date: 2023-02-09

Last Posted Date: 2024-10-01

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT05720494

Locations: 🇺🇸
Clinical Site 1, Salt Lake City, Utah, United States

A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: JZP441
Drug: Placebo

First Posted Date: 2022-12-14

Last Posted Date: 2024-07-30

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT05651152

Locations: 🇺🇸
Clinical Site 1, Eatontown, New Jersey, United States
🇺🇸
Clinical Site 2, New York, New York, United States

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease
Tremor

Interventions: Drug: Placebo
Drug: Suvecaltamide

First Posted Date: 2022-12-08

Last Posted Date: 2025-01-28

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 169

Registration Number: NCT05642442

Locations: 🇵🇱
Neurologia Slaska Centrum Medyczne, Katowice, Poland
🇵🇱
ETG Neuroscience Sp. z o.o., Warszawa, Poland
🇺🇸
Dent Neurologic Institute, Amherst, New York, United States

and more 34 locations

A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: JZP341

First Posted Date: 2022-11-30

Last Posted Date: 2024-05-28

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT05631327

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
SCRI HealthOne, Denver, Colorado, United States

and more 5 locations

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Phase 1

Recruiting

Conditions: Solid Tumor
Advanced Cancer
Metastatic Cancer

Interventions: Drug: JZP815

First Posted Date: 2022-09-27

Last Posted Date: 2025-02-04

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 332

Registration Number: NCT05557045

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 5 locations

Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

Recruiting

Conditions: Lennox Gastaut Syndrome
Dravet Syndrome
Tuberous Sclerosis Complex

Interventions: Drug: Epidiolex 100 mg/mL Oral Solution

First Posted Date: 2022-08-03

Last Posted Date: 2025-05-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05485831

Locations: 🇮🇹
Policlinico Sant'Orsola di Bologna, Bologna, Italy
🇮🇹
NPI AOU Mater Domini Università Magna Graecia, Catanzaro, Italy
🇮🇹
Università degli studi "G. D'annunzio" Chieti, Chieti, Italy

and more 12 locations

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

Phase 3

Terminated

Conditions: Seizures Associated With EMAS

Interventions: Drug: GWP42003-P
Drug: Placebo

First Posted Date: 2022-03-21

Last Posted Date: 2025-02-03

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT05288283

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Dell's Children's Hospital, Austin, Texas, United States

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy